On the positive side, the duration of the apnea events was shortened by 21 minutes (statistically significant). So while the apnea events still occur, they are of shorter duration.
The problem is that at 900 mg there's also a 20% reduction in time asleep, and the cummulative effects of insomnia should be worse/additive over time. The 900 mg dose was 'near the limits of tolerability', so can they lower the dose without losing the modest SA therapeutic effect? A big question for a future trial.
As Neuro and Davidal said, ADHD looks like our best bet, and RD/SA could be packaged together if Cortex can get the RD rights back from Valeant. But next on the agenda for Varney -- raise some interim money/some type of deal. I figure they've got ~3-4 months before the money situation becomes critical again.
Market Data 
Markets 
AI
